Lead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus ahead
![Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13175480.ece/ALTERNATES/schema-16_9/20210505-074305-L-1920x1920we%2520(1).jpg)
Novo Nordisk is looking into a growth-heavy Q2, as it has had tailwind with diabetes 2 drugs Ozempic and Rybelsus, and as the demand is high for its new weight-loss treatment Wegovy.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly specifies guidance for this year's revenue
For subscribers